CDK4 and metastatic neoplasm: In patients with prior CDK4/6 inhibitor exposure for metastatic disease (n = 561), the median TTNT and TTD on elacestrant were 6.1 and 4.3 months, respectively, compared with 10.3 and 5.3 months in those without prior CDK4/6 blockade (n = 181) (TTNT adjusted HR = 1.52, 95% CI, 1.12–2.07; TTD adjusted HR = 1.10, 95% CI, 0.85–1.43; Supplementary Fig. S3).